(qEEG) Brain Mapping
The electrical activity produced by the brain (EEG) is carefully acquired using a 19-channel electrode cap.
It is then compared with a database of normal EEG, used by hospitals all over the world, to identify problems, predict successful treatment, and track treatment progress.
© 2016-2017 Applied Neuroscience, Inc.
Gray Matters uses swLORETA, the latest in 3D qEEG imaging, to identify the source of abnormal brain activity with unrivalled accuracy.
qEEG brain mapping allows brain activity to be seen and measured, going beyond symptoms to understanding the underlying cause.
Consistent with a growing emphasis on diagnosis using empirical data, qEEG helps to diagnose and predict cognitive issues based on neurologically distinct brain activity:
ADHD Excess frontal theta →
(cortical low arousal)
Anxiety Excess high beta →
(cortical high arousal)
Post Concussive Syndrome →
Expert qEEG assessment, combined with experienced treatment planning, produces extraordinary results:
qEEG is the definitive measurement of brain activity, frozen in time. Should function change for any reason (for example due to injury, or simply aging), we are able to train the brain back towards this initial recording. This is why Gray Matters is involved in baseline brain mapping in athletics.
Diagnosis based on measured brain function:
Better diagnosis, better outcomes.
Despite advances in brain imaging, most people are still diagnosed based on their symptoms, and the subjective opinion of their clinician. As a result, treatments, (including medications) are often unsuccessful, costly, and can be accompanied by a variety of undesirable side-effects.
Quantitative EEG (qEEG) measures actual brain function, comparing it to a database of normal brain function used by hospitals all over the world. By seeing how an individual differs from this norm, we can diagnose and predict difficulties with incredible accuracy. This allows us to create individualized treatment plans, customized for success.
In the U.S. the National Institute of Health (NIMH) is promoting a shift towards the use of biomarkers in diagnosis, rather than the subjective criteria commonly used. qEEG is emerging as a reliable method for identifying disorders and predicting medication response – reducing the need for medication trials that still predominate in mental health.